US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Redhill Biopharma

1.93

-0.1650-7.88%

Post-market: 1.930.00000.00%19:53 EDT

Volume:73.72K

Turnover:143.77K

Market Cap:3.38M

PE:-0.29

High:2.18

Open:2.18

Low:1.76

Close:2.10

Loading ...

Overview Company News Filings

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Obtains Allowance for Chinese Patent Application for COVID-19 Treatment

MT Newswires Live

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill Biopharma Gets Nasdaq Noncompliance Notice

MT Newswires Live

RedHill Biopharma receives non-compliance letter from Nasdaq

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Redhill Biopharma FY 2024 EPS $(0.00) Down From $0.01 YoY, Sales $8.04M Up From $6.53M YoY

Press Release: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Biopharma Begins Phase 2 Study of Opaganib, Darolutamide for Advanced Prostate Cancer; Shares Rise

MT Newswires Live

RedHill Biopharma begins Phase 2 study of prostate cancer combination

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

RedHill Biopharma’s opaganib shows radioprotective activity in study

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court

RedHill Biopharma Awarded $8 Million in Legal Case Against Kukbo

MT Newswires Live

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RDHL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RDHL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RDHL\",,,,,undefined,":{"symbol":"RDHL","market":"US","secType":"STK","nameCN":"Redhill Biopharma","latestPrice":1.93,"timestamp":1746561600000,"preClose":2.095,"halted":0,"volume":73719,"hourTrading":{"tag":"盘后","latestPrice":1.93,"preClose":1.93,"latestTime":"19:53 EDT","volume":29,"amount":55.6879,"timestamp":1746575610338},"delay":0,"floatShares":1748693,"shares":1752007,"eps":-6.709557,"marketStatus":"Closed","change":-0.165,"latestTime":"05-06 16:00:00 EDT","open":2.18,"high":2.18,"low":1.76,"amount":143773.9961463,"amplitude":0.200477,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-6.709557,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746604800000},"marketStatusCode":5,"adr":0,"adrRate":10000,"listingDate":1356584400000,"exchange":"NASDAQ","adjPreClose":2.095,"preHourTrading":{"tag":"盘前","latestPrice":2.18,"preClose":2.11,"latestTime":"09:25 EDT","volume":140,"amount":302.67001799999997,"timestamp":1746537913274},"postHourTrading":{"tag":"盘后","latestPrice":1.93,"preClose":1.93,"latestTime":"19:53 EDT","volume":29,"amount":55.6879,"timestamp":1746575610338},"volumeRatio":2.968112,"impliedVol":4.3396,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RDHL\",,,,,undefined,":{"symbol":"RDHL","floatShares":1748693,"roa":"-37.28%","roe":"-1708.61%","lyrEps":-6.709557,"volumeRatio":2.968112,"shares":1752007,"dividePrice":0,"high":2.18,"amplitude":0.200477,"preClose":2.095,"low":1.76,"week52Low":1.72,"pbRate":"-0.72","psRate":"0.42","week52High":20.275,"institutionHeld":0,"latestPrice":1.93,"eps":-6.709557,"divideRate":0,"volume":73719,"delay":0,"ttmEps":-6.709557,"open":2.18,"prevYearClose":6.21,"prevWeekClose":2.07,"prevMonthClose":2.205,"prevQuarterClose":2.66,"fiveDayClose":2.23,"twentyDayClose":2.05,"sixtyDayClose":5.5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RDHL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532810145","title":"RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2532810145","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532810145?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:00","pubTimestamp":1746183600,"startTime":"0","endTime":"0","summary":"The first part of the program, led by a faculty of William Chey, MD, Vivian Asamoah, MD and Shailja Shah, MD, MPH, will take place May 6 during a major U.S. gastroenterology meeting. H. pylori is classified by the World Health Organization  as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer[1]and a major risk factor for peptic ulcer disease[2]. With almost half the global population infected by H. pylori[3], its treatment represents a billion-dollar market opportunity[4]. RALEIGH, N.C., May 2, 2025 /PRNewswire/ --RedHill Biopharma Ltd.  , a specialty biopharmaceutical company, today announced its support of an independent medical education grant that includes a new two-part H. PyloriCME program, developed by Medscape and designed to advance clinical knowledge and improve patient outcomes. The first part of the program, a livestreamed event entitled \"Let's Get Social About H. pylori Management\" led by William Chey, MD, Vivian Asamoah, MD and Shailja Shah, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-supported-medscape-h-pylori-110000775.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-supported-medscape-h-pylori-110000775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","CME","IE00B42XCP33.USD","LU2506951958.HKD","LU0158827948.USD","BK4121","PPI","LU1116320901.HKD","LU0731783048.USD","LU0912757837.SGD","LU2133065610.SGD","LU0265550946.USD","LU0823417653.USD","LU0795875086.SGD","LU0545562505.USD","LU1228905540.USD","LU2089283258.USD","IE00BVYPNV92.GBP","LU1481011911.USD","SLE","LU0772969993.USD","BK4215","BK4124","LU0795875169.SGD","UAE","SEER","LU1732800096.USD","BK4007","IE0034235188.USD","LU2506952097.USD","LU0823417737.USD","TEN","LU1509826696.USD","LU0265550359.USD","BK4144","BK4570","BK4112","BK4077","LU1732799900.SGD","LU0950375773.USD","LU1481011671.HKD","IE00B3T34201.USD","IE00BVYPNW00.USD","LU1718418525.SGD","MAA","RDHL","LU2506952170.USD","LU1116320737.USD","LU2506951875.HKD","BK4588"],"gpt_icon":0},{"id":"2531023066","title":"RedHill Biopharma Obtains Allowance for Chinese Patent Application for COVID-19 Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2531023066","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531023066?lang=en_us&edition=fundamental","pubTime":"2025-04-29 00:53","pubTimestamp":1745859192,"startTime":"0","endTime":"0","summary":"RedHill Biopharma  said Monday it has received allowance for the composition-of-matter patent application for its proprietary investigational compound RHB-107, a potential oral treatment for COVID-19, from the China National Intellectual Property Administration.The patent protects the molecular structure of the compound and includes coverage for treatment of SARS-CoV-2, including wild-type and emerging variants, the company said.RedHill said it acquired the exclusive worldwide rights to RHB-107, excluding China, Hong Kong, Taiwan and Macao, from Germany's Heidelberg Pharma AG, for all indications.Price: 2.26, Change: -0.15, Percent Change: -6.22","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BNTX","RDHL","BK4007"],"gpt_icon":0},{"id":"2530472582","title":"RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107","url":"https://stock-news.laohu8.com/highlight/detail?id=2530472582","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530472582?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:03","pubTimestamp":1745838180,"startTime":"0","endTime":"0","summary":"Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims. COVID-19 Therapeutic Use: Includes coverage for treatment of SARS-CoV-2, including wild-type and emerging variants. This patent grant enhances RedHill's strategic positioning in the global COVID-19 therapeutic space, a market still expected to be worth more than $3 billion in 2025[1], and expands its patent footprint in Asia, a key pharmaceutical market. RHB-107 successfully met the primary endpoint of safety and tolerability, delivering promising reduction in hospitalization efficacy results in a U.S. Phase 2 COVID-19 study[2]. Additional clinical data expected from the externally non-dilutive funded PROTECT study, supported by the U.S. Department of Defense. RHB-107 is a novel, patient-friendly oral, once-daily, host-directed potential broad-acting antiviral expected to act independently of viral spike protein mutations[3]. Data f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-biopharma-secures-allowance-key-110300040.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-biopharma-secures-allowance-key-110300040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","BK4548","BK4551","BK4535","BK4585","RDHL","BK4588","BK4568","BNTX"],"gpt_icon":0},{"id":"2528737947","title":"RedHill Biopharma Gets Nasdaq Noncompliance Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2528737947","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528737947?lang=en_us&edition=fundamental","pubTime":"2025-04-18 04:17","pubTimestamp":1744921028,"startTime":"0","endTime":"0","summary":"RedHill Biopharma  said late Thursday it received a notice from Nasdaq for noncompliance with a listing rule.The company failed to meet the minimum $2.5 million stockholders' equity requirement, based on its annual report filed April 10.RedHill said it has until May 30 to submit a plan to regain compliance, the company said.Shares of RedHill were down nearly 2% in after-hours trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","RDHL","LU2210150020.SGD","NDAQ","IE00BGHQF748.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD",".IXIC","IE00B3QW5Z07.USD","BK4007","LU2095319765.USD","BK4112","NQmain","BK4588"],"gpt_icon":0},{"id":"2528773750","title":"RedHill Biopharma receives non-compliance letter from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2528773750","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528773750?lang=en_us&edition=fundamental","pubTime":"2025-04-18 04:06","pubTimestamp":1744920373,"startTime":"0","endTime":"0","summary":"RedHill Biopharma (RDHL) announced that the Company received a written notification from the Listing Qualifications Department of the Nasdaq Stock ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/redhill-biopharma-receives-non-compliance-letter-from-nasdaq?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/redhill-biopharma-receives-non-compliance-letter-from-nasdaq?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2210149790.SGD","BK4007","SQQQ","NDAQ",".IXIC","TQQQ","BK4588","QID","BK4585","USAW.SI","IE00B64PRP62.GBP","NVIW.SI","USJW.SI","QLD","MNQmain","IE00BKPKM429.USD","TSYW.SI","LU2095319765.USD","PSQ","RDHL","NQmain","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2528776808","title":"RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2528776808","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528776808?lang=en_us&edition=fundamental","pubTime":"2025-04-18 04:01","pubTimestamp":1744920060,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel and RALEIGH, N.C., April 17, 2025 /PRNewswire/ --RedHill Biopharma Ltd. , a specialty biopharmaceutical company, today announced that the Company received a written notification  from the Listing Qualifications Department of the Nasdaq Stock Market LLC  dated April 15, 2025, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5550 .The Rule requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders' equity for continued listing. However, based on the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed on April 10, 2025, the Company reported a stockholders' deficit of $4,683,000, and does not meet the alternatives of market value of listed securities or net income from continuing operations, and is thus non-compliant with the Rule.The Company is looking into various options available to regain compliance and maintain its continued listing on the Nasdaq Capit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-biopharma-receives-nasdaq-notification-200100141.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-biopharma-receives-nasdaq-notification-200100141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","PSQ","TQQQ","MNQmain","LU2210150020.SGD","LU2095319765.USD","BK4215","NVIW.SI",".IXIC","TSYW.SI","IE00BGHQF748.EUR","BK4588","SQQQ","USJW.SI","NQmain","BK4585","IE00BKPKM429.USD","BK4112","EQR","QID","LU2210149790.SGD","IE00B64PRP62.GBP","USAW.SI","RDHL","BK4007","NDAQ","QLD"],"gpt_icon":1},{"id":"2527294609","title":"RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption","url":"https://stock-news.laohu8.com/highlight/detail?id=2527294609","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527294609?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:00","pubTimestamp":1744801200,"startTime":"0","endTime":"0","summary":"GLP-1 comparable efficacy: Opaganib's positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and improved metabolic markers on par with semaglutide in preclinical models. Novel mechanism of action, formulation and administration: Opaganib is a differentiated oral, non-peptide therapeutic that targets sphingosine kinase-2 , potentially avoiding common Glucagon-like peptide-1  inhibitor side effects and administration burdens. TEL AVIV, Israel and RALEIGH, N.C., April 16, 2025 /PRNewswire/ -- RedHill Biopharma Ltd.  , a specialty biopharmaceutical company, today announced the new publication[2] of positive in vivo data, in the journal Diabetes, Metabolic Syndrome and Obesity, in an article entitled \"Opaganib Promotes Weight Loss and Suppresses High-Fat Diet -Induced Obesity and Glucose Intolerance\". The data indicates that opaganib[3] effectively suppresses the loss of metabolic control in mice on a HFD, suggesting that opagani","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-biopharmas-positive-opaganib-weight-110000215.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-biopharmas-positive-opaganib-weight-110000215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4009","ASPR","BK4116","CD","BK4007","RDHL"],"gpt_icon":0},{"id":"2526568937","title":"Redhill Biopharma FY 2024 EPS $(0.00) Down From $0.01 YoY, Sales $8.04M Up From $6.53M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2526568937","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526568937?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:52","pubTimestamp":1744285965,"startTime":"0","endTime":"0","summary":"Redhill Biopharma (NASDAQ:RDHL) reported quarterly losses of $(0.02) per share. This is a 300 percent decrease over earnings of $0.01 per share from the same period last year.  The company reported $8.04 million in sales","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44731842/redhill-biopharma-fy-2024-eps-0-00-down-from-0-01-yoy-sales-8-04m-up-from-6-53m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RDHL"],"gpt_icon":0},{"id":"2526568893","title":"Press Release: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2526568893","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526568893?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:48","pubTimestamp":1744285680,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel and RALEIGH, N.C., April 10, 2025. Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights:. Pharmaceuticals with RHB-102 for up to $60 million in potential milestone. -- Approximately $8 million plus legal costs NY Supreme Court summary. -- Bayer-supported Phase 2 combination study of opaganib and Bayer's. statistically significant 64% improvement in efficacy; FDA path to. divestiture transaction and reduced R&D spend, cash burn slashed by 74%. TEL AVIV, Israel and RALEIGH, N.C., April 10, 2025 /PRNewswire/ -- RedHill Biopharma Ltd.  , a specialty biopharmaceutical company, today reported its full-year 2024 financial results and operational highlights and associated filing of its annual report on Form 20-F for the year ended December 31, 2024.Dror Ben-Asher, RedHill's Chief Executive Officer, said: \"We have undergone an extensive overhaul reshaping ourselves financial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4215","BK4116","R","UAE","BK4022","BK4007","RDHL","MAA","BK4585","BK4232","CD"],"gpt_icon":0},{"id":"2514806475","title":"RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2514806475","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514806475?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Guy Goldberg, RedHill's Chief Business Officer, presents today a business update at the European Life Sciences CEO Forum. The recent out-licensing of RHB-102[1] to Hyloris  in a potential $60 million plus royalties deal. \"We have had a very positive start to 2025, making significant progress on multiple fronts. We have just announced the out-licensing of RHB-102 to Hyloris, in a deal worth up to $60 million in potential milestone payments plus additional royalties on revenues. We also recently announced the initiation of a Bayer-funded Phase 2 clinical study of opaganib in combination with Bayer's darolutamide for advanced prostate cancer, for which there are very limited options. This is in addition to the multiple U.S. government- and academia-supported R&D programs with key 2025 potential catalysts, including for radiation injury protection, oncology, and various pandemic preparedness indications,\" said Guy Goldberg, RedHill's Chief Business Officer. \"The commercial team are working","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-presents-business-sachs-european-120000746.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-presents-business-sachs-european-120000746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RDHL","BK4007","FET","BK4179"],"gpt_icon":0},{"id":"2514241098","title":"RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2514241098","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514241098?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":"- Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues, in return for exclusive rights to develop and commercialize RHB-102  across all indications and territories outside the United States, Canada and Mexico. - RedHill intends to continue development of RHB-102 for FDA approval in the U.S., if granted. Hyloris will be responsible for all development, regulatory and commercialization activities related to RHB-102 in its territories. \"Ondansetron ER will be a valuable addition to supportive care in oncology and post-surgical settings, where sustained relief from nausea is essential,\" said Thomas Jacobsen, Co-Chief Executive Officer of Hyloris. \"We are committed to delivering innovative solutions that enhance patient comfort and streamline therapy, especially in areas where reducing tre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-licenses-rhb-102-commercialization-120000609.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-licenses-rhb-102-commercialization-120000609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAA","BK4215","BK4585","BK4588","RDHL","BK4007"],"gpt_icon":0},{"id":"2508463173","title":"RedHill Biopharma Begins Phase 2 Study of Opaganib, Darolutamide for Advanced Prostate Cancer; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2508463173","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508463173?lang=en_us&edition=fundamental","pubTime":"2025-02-04 23:37","pubTimestamp":1738683462,"startTime":"0","endTime":"0","summary":"RedHill Biopharma  shares were up Tuesday after the company said it started a phase 2 clinical study of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer.The 80-patient trial will test the potentially enhancing effect of opaganib in overcoming resistance to standard of care androgen receptor pathway inhibition treatment.The study is financially backed by Bayer and the Ramsay Hospital Research Foundation, RedHill said.Price: 6.18, Change: +0.43, Percent Change: +7.48","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK6088","BK4007","BK4157","IE00B7SZL793.SGD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","AEIS","IE0031619046.USD","RDHL","BK6522","BLZ.SI"],"gpt_icon":0},{"id":"2508696453","title":"RedHill Biopharma begins Phase 2 study of prostate cancer combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2508696453","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508696453?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:25","pubTimestamp":1738671954,"startTime":"0","endTime":"0","summary":"RedHill Biopharma (RDHL) announced the initiation of a Phase 2 clinical study to evaluate the efficacy of its opaganib candidate in combination wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/redhill-biopharma-begins-phase-2-study-of-prostate-cancer-combination?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/redhill-biopharma-begins-phase-2-study-of-prostate-cancer-combination?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RDHL"],"gpt_icon":0},{"id":"2508458639","title":"RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2508458639","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508458639?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:00","pubTimestamp":1738670400,"startTime":"0","endTime":"0","summary":"The 80-patientplacebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer , testing the potentially enhancing effect of opaganib in patients with a poor prognosis. The study is being financially supported by Bayer  and the Ramsay Hospital Research Foundation, and will be led by Professor Lisa Horvath from Chris O'Brien Lifehouse and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group . The study will utilize a companion lipid biomarker test  to select mCRPC patients who have a poor prognosis due to standard of care treatment and who may benefit from an opaganib + darolutamide combination treatment approach. Primary endpoint will be improved 12-month radiographic progression-free survival . Prostate cancer  is the second most diagnosed cancer in the world, with around 1.5 million new cases per year, causing almost 400,000 deaths. People with mC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-announces-initiation-phase-2-120000083.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-announces-initiation-phase-2-120000083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","AR","BK4157","BK4211","BK4165","IE0031619046.USD","BK4209","IE00B7SZL793.SGD","ASPR","AEIS","BK4213","BK4195","RDHL","PC","BK4009","BK4192","BK4007","IE00B66KJ199.SGD","PFS","ADT"],"gpt_icon":0},{"id":"2505145229","title":"RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published","url":"https://stock-news.laohu8.com/highlight/detail?id=2505145229","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505145229?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:00","pubTimestamp":1737460800,"startTime":"0","endTime":"0","summary":"Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without requiring prior therapeutic steps or authorization. Additionally, new data describing the foundations for Talicia's recent FDA-approved label change to a more convenient three-times daily  \"breakfast, lunch, and dinner\" dosing routine, supporting patient adherence, has been published in the Journal of Clinical Pharmacology. The published data describe the use of physiologically-based pharmacokinetic  modeling and simulation to demonstrate pharmacokinetic equivalence of the TID regimen to the previous every 8-hour  dosing regimen. H. pylori infection affects approximately 35% of the U.S. adult population and is classified by the World Health Organization  as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer and a major risk factor for peptic ulcer disease. The result of a successful collaboration with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhills-talicia-adds-8-million-120000783.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhills-talicia-adds-8-million-120000783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ITT","BNTX","RDHL","LU0053671581.USD","BK4121","BK4551","BK4585","BK4077","BK4139","BK4535","SLE","BK4588","BK4568","LU0054578231.USD","SEER","BK4161","BK4007","BK4124","PPI","BK4570","TEN","BK4144","BK4548"],"gpt_icon":0},{"id":"2490928860","title":"RedHill Biopharma’s opaganib shows radioprotective activity in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2490928860","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490928860?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:17","pubTimestamp":1733833047,"startTime":"0","endTime":"0","summary":"RedHill Biopharma (RDHL) announced positive results from new in vivo studies of opaganib as a treatment for gastrointestinal acute radiation syndro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/redhill-biopharmas-opaganib-shows-radioprotective-activity-in-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/redhill-biopharmas-opaganib-shows-radioprotective-activity-in-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RDHL"],"gpt_icon":0},{"id":"2490013530","title":"Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2490013530","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490013530?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832000,"startTime":"0","endTime":"0","summary":"Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological incident. There are currently no known approved therapies for gastrointestinal acute radiation syndrome . Positive results from new in vivo studies of opaganib as a treatment for GI-ARS, undertaken as part of the U.S. government's Radiation and Nuclear Countermeasures Program product pipeline development contract, further confirm opaganib's protective activity. \"There are currently no known approved therapies for GI-ARS. Growing geopolitical tensions and Homeland Security concerns call for development of new potential therapies that can be quickly and easily deployed in the event of a mass casualty nuclear or radiological incident,\" said Gilead Raday, RedHill's Chief Operating Officer and Head of Research and Development. \"Opaganib, as an oral, small molecule pill that is highly s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YJPZyTSOAz79b9jtDhF1MA--~B/aD0yMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4fefa5aba37b5a4ecc13dada34b1c97d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YJPZyTSOAz79b9jtDhF1MA--~B/aD0yMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4fefa5aba37b5a4ecc13dada34b1c97d"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/radioprotective-activity-redhills-opaganib-gi-120000463.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/radioprotective-activity-redhills-opaganib-gi-120000463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","IE00B7SZL793.SGD","AEIS","BK4139","ASPR","RDHL","BK4551","BK4588","BK4007","IE0031619046.USD","BK4548","IE00B66KJ199.SGD","BNTX","BK4157","BK4585","BK4535","IE00B19Z4B17.USD","BK4009"],"gpt_icon":0},{"id":"2488919600","title":"RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2488919600","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488919600?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:18","pubTimestamp":1733228308,"startTime":"0","endTime":"0","summary":"RedHill Biopharma  announced that the Company has been awarded approximately $8 million, plus costs in a summary judgment by the Supreme Court of the State of New York, New York County, in its legal proceedings against Kukbo Co. Ltd., domiciled in South Korea. The case refers to Kukbo’s failure to make agreed payments to RedHill, pursuant to a Subscription Agreement, dated October 25, 2021, and a subsequent Exclusive License Agreement, dated March 14, 2022, entered into by the two companies.Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. RedHill Biopharma to Present Opaganib at U.S. Defense Conference. RedHill Biopharma and Duke Collaborate on Opaganib Development. RedHill Biopharma signs research pact with Duke University School of Medicine. RedHill Biopharma Partners with BARDA for Ebola Treatment. RedHill Biopharma secures federal BARDA funding for opaganib in Ebola tre","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.2OcvspZzvCzzeMPm.N5LA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.2OcvspZzvCzzeMPm.N5LA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-biopharma-awarded-judgement-approx-121828723.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-biopharma-awarded-judgement-approx-121828723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","RDHL"],"gpt_icon":0},{"id":"2488360869","title":"RedHill Biopharma Awarded $8 Million in Legal Case Against Kukbo","url":"https://stock-news.laohu8.com/highlight/detail?id=2488360869","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488360869?lang=en_us&edition=fundamental","pubTime":"2024-12-02 23:37","pubTimestamp":1733153866,"startTime":"0","endTime":"0","summary":"RedHill Biopharma  said Monday it has been awarded approximately $8 million, including nearly $1.5 million in interest, by the New York Supreme Court in a legal case against Kukbo.The court ruled that Kukbo failed to make payments to RedHill Biopharma according to their agreements on Oct. 25, 2021, and Mar. 14, 2022, the company said.Kukbo has the right to appeal the court's decision, it added.RDHL shares were up over 4% in recent trading.Price: 8.52, Change: +0.34, Percent Change: +4.16","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RDHL","BK4007"],"gpt_icon":0},{"id":"2488508859","title":"RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2488508859","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488508859?lang=en_us&edition=fundamental","pubTime":"2024-12-02 20:00","pubTimestamp":1733140800,"startTime":"0","endTime":"0","summary":"RedHill has been awarded a judgment of approximately $8 million plus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd. The Court dismissed the entirety of Kukbo's counterclaims, ruling in favor of RedHill's demonstrated good faith commitment to the spirit and the letter of the agreements. TEL-AVIV, Israel and RALEIGH, N.C., Dec. 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.  , a specialty biopharmaceutical company, today announced that the Company has been awarded approximately $8 million , plus costs in a summary judgment by the Supreme Court of the State of New York, New York County , in its legal proceedings  against Kukbo Co. Ltd. , domiciled in South Korea.Dror Ben-Asher, RedHill's CEO: \"RedHill thanks the Court for this crystal-clear judgment, affirming the Company's just position from the beginning of the relationship, and in making correct provision for full reparation for the contractual breaches. The Company is also gra","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YJPZyTSOAz79b9jtDhF1MA--~B/aD0yMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4fefa5aba37b5a4ecc13dada34b1c97d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YJPZyTSOAz79b9jtDhF1MA--~B/aD0yMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4fefa5aba37b5a4ecc13dada34b1c97d"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-biopharma-awarded-judgment-approximately-120000878.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-biopharma-awarded-judgment-approximately-120000878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4568","BK4139","BK4551","BNTX","BK4585","BK4007","BK4535","RDHL","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RDHL\",params:#limit:5,,,undefined,":[{"date":"2025-04-10","symbol":"RDHL","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1744272000000,"name":null,"time":"Pre-Market","dateTimestamp":1744257600000,"actualEps":null},{"market":"US","date":"2024-08-29","symbol":"RDHL","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1724904000000,"reportTimeType":"pre","actualEps":900},{"market":"US","date":"2024-08-20","symbol":"RDHL","defaultRemindTime":1724160600000,"type":"split","dateTimestamp":1724126400000,"forFactor":25,"toFactor":1,"ratio":25},{"date":"2024-04-08","symbol":"RDHL","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1712563200000,"name":null,"time":"Pre-Market","dateTimestamp":1712548800000,"actualEps":null},{"market":"US","date":"2023-08-17","symbol":"RDHL","fiscalQuarterEnding":"2023/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1692244800000,"reportTimeType":"pre","actualEps":36}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RDHL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RDHL\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RDHL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RDHL","date":"2025-05-05","current":-0.438637,"percent":0.536526,"low":-7.733807,"twenty":-4.76208,"median":-0.534303,"eighty":-0.083702,"high":10.74545,"avg":-1.774018,"sd":2.504897,"marketCap":3626654},"quantilePoints":[{"date":"2020-05-08","current":-5.752647,"twenty":-35.498177,"median":-22.672212,"eighty":-4.556019,"marketCap":243359964},{"date":"2020-05-15","current":-5.602578,"twenty":-35.303581,"median":-16.46512,"eighty":-4.556019,"marketCap":237011443},{"date":"2020-05-22","current":-6.136156,"twenty":-35.132879,"median":-13.876006,"eighty":-4.556019,"marketCap":259583961},{"date":"2020-05-29","current":-5.063807,"twenty":-34.717472,"median":-13.70246,"eighty":-4.556019,"marketCap":251119267},{"date":"2020-06-05","current":-4.850445,"twenty":-34.470365,"median":-13.606045,"eighty":-4.556019,"marketCap":240538399},{"date":"2020-06-12","current":-5.006911,"twenty":-34.310575,"median":-13.339941,"eighty":-4.556019,"marketCap":248297702},{"date":"2020-06-19","current":-4.793548,"twenty":-34.169631,"median":-13.104688,"eighty":-4.556019,"marketCap":237716834},{"date":"2020-06-26","current":-5.234497,"twenty":-33.984565,"median":-12.846297,"eighty":-4.556019,"marketCap":259583961},{"date":"2020-07-02","current":-4.829108,"twenty":-33.832592,"median":-9.728528,"eighty":-4.556019,"marketCap":239480312},{"date":"2020-07-10","current":-4.80066,"twenty":-33.759056,"median":-6.519501,"eighty":-4.556019,"marketCap":238069530},{"date":"2020-07-17","current":-4.921566,"twenty":-33.563093,"median":-6.416203,"eighty":-4.551971,"marketCap":244065355},{"date":"2020-07-24","current":-4.850445,"twenty":-33.358674,"median":-6.39428,"eighty":-4.551971,"marketCap":240538399},{"date":"2020-07-31","current":-5.639886,"twenty":-32.905123,"median":-6.376011,"eighty":-4.551971,"marketCap":279687610},{"date":"2020-08-07","current":-6.223078,"twenty":-32.711984,"median":-6.322927,"eighty":-4.551971,"marketCap":308608650},{"date":"2020-08-14","current":-5.013652,"twenty":-32.584653,"median":-6.303888,"eighty":-4.551971,"marketCap":274397176},{"date":"2020-08-21","current":-5.187648,"twenty":-32.540489,"median":-6.244291,"eighty":-4.551971,"marketCap":283919958},{"date":"2020-08-28","current":-5.097428,"twenty":-32.41251,"median":-6.168097,"eighty":-4.551971,"marketCap":278982219},{"date":"2020-09-04","current":-4.794546,"twenty":-32.117752,"median":-6.130654,"eighty":-4.551971,"marketCap":262405526},{"date":"2020-09-11","current":-6.412061,"twenty":-32.063378,"median":-6.10232,"eighty":-4.551971,"marketCap":350932122},{"date":"2020-09-18","current":-6.805163,"twenty":-31.929287,"median":-6.10232,"eighty":-4.551971,"marketCap":372446553},{"date":"2020-09-25","current":-6.896634,"twenty":-31.718696,"median":-6.10232,"eighty":-4.551971,"marketCap":377452774},{"date":"2020-10-02","current":-6.951315,"twenty":-31.595992,"median":-6.10232,"eighty":-4.551971,"marketCap":380445462},{"date":"2020-10-09","current":-6.787272,"twenty":-31.390964,"median":-6.10232,"eighty":-4.551971,"marketCap":371467398},{"date":"2020-10-16","current":-6.93081,"twenty":-31.302212,"median":-6.10232,"eighty":-4.551971,"marketCap":379323204},{"date":"2020-10-23","current":-6.616394,"twenty":-31.249119,"median":-6.10232,"eighty":-4.551971,"marketCap":362115248},{"date":"2020-10-30","current":-5.714159,"twenty":-31.173361,"median":-6.071627,"eighty":-4.551971,"marketCap":312735896},{"date":"2020-11-06","current":-5.967058,"twenty":-31.065851,"median":-6.048075,"eighty":-4.551971,"marketCap":326577078},{"date":"2020-11-13","current":-4.82232,"twenty":-31.011868,"median":-6.025426,"eighty":-4.551971,"marketCap":306376434},{"date":"2020-11-20","current":-5.299252,"twenty":-30.954467,"median":-6.001445,"eighty":-4.551971,"marketCap":336677400},{"date":"2020-11-27","current":-5.210931,"twenty":-30.805368,"median":-5.975816,"eighty":-4.551971,"marketCap":331066110},{"date":"2020-12-04","current":-5.193267,"twenty":-30.640777,"median":-5.96065,"eighty":-4.551971,"marketCap":329943852},{"date":"2020-12-11","current":-4.757551,"twenty":-30.494746,"median":-5.930056,"eighty":-4.551971,"marketCap":302261488},{"date":"2020-12-18","current":-5.03429,"twenty":-30.330356,"median":-5.904203,"eighty":-4.551971,"marketCap":319843530},{"date":"2020-12-24","current":-5.48767,"twenty":-30.197728,"median":-5.885787,"eighty":-4.551971,"marketCap":348648152},{"date":"2020-12-31","current":-4.757551,"twenty":-29.999106,"median":-5.873329,"eighty":-4.551971,"marketCap":302261488},{"date":"2021-01-08","current":-4.945969,"twenty":-29.718203,"median":-5.837117,"eighty":-4.551971,"marketCap":314232240},{"date":"2021-01-15","current":-4.86347,"twenty":-29.111508,"median":-5.813541,"eighty":-4.549485,"marketCap":308990815},{"date":"2021-01-22","current":-5.00093,"twenty":-29.015998,"median":-5.788953,"eighty":-4.549485,"marketCap":317724068},{"date":"2021-01-29","current":-5.511496,"twenty":-28.865126,"median":-5.771221,"eighty":-4.549485,"marketCap":350161866},{"date":"2021-02-05","current":-5.714413,"twenty":-28.766859,"median":-5.758456,"eighty":-4.549485,"marketCap":363053811},{"date":"2021-02-12","current":-6.349348,"twenty":-28.545396,"median":-5.758456,"eighty":-4.549485,"marketCap":403393124},{"date":"2021-02-19","current":-7.14138,"twenty":-28.497771,"median":-5.758456,"eighty":-4.549485,"marketCap":453713297},{"date":"2021-02-26","current":-6.218434,"twenty":-28.441809,"median":-5.758456,"eighty":-4.549485,"marketCap":395075740},{"date":"2021-03-05","current":-5.717846,"twenty":-28.3042,"median":-5.746204,"eighty":-4.549485,"marketCap":363271910},{"date":"2021-03-12","current":-5.768963,"twenty":-28.219686,"median":-5.735972,"eighty":-4.549485,"marketCap":366519552},{"date":"2021-03-19","current":-4.607121,"twenty":-28.152628,"median":-5.735322,"eighty":-4.549485,"marketCap":350938246},{"date":"2021-03-26","current":-4.472338,"twenty":-28.087056,"median":-5.718991,"eighty":-4.547469,"marketCap":340671436},{"date":"2021-04-01","current":-4.600995,"twenty":-27.988657,"median":-5.71613,"eighty":-4.536887,"marketCap":350471573},{"date":"2021-04-09","current":-4.478465,"twenty":-27.883994,"median":-5.700593,"eighty":-4.511214,"marketCap":341138109},{"date":"2021-04-16","current":-4.349809,"twenty":-27.788618,"median":-5.682251,"eighty":-4.495899,"marketCap":331337972},{"date":"2021-04-23","current":-4.325303,"twenty":-27.688075,"median":-5.666729,"eighty":-4.463806,"marketCap":329471279},{"date":"2021-04-30","current":-4.178267,"twenty":-27.606817,"median":-5.654623,"eighty":-4.426449,"marketCap":318271122},{"date":"2021-05-07","current":-3.835183,"twenty":-27.493758,"median":-5.638972,"eighty":-4.404567,"marketCap":292137423},{"date":"2021-05-14","current":-3.810677,"twenty":-27.116471,"median":-5.618467,"eighty":-4.374659,"marketCap":290270730},{"date":"2021-05-21","current":-4.319176,"twenty":-26.978474,"median":-5.611319,"eighty":-4.347522,"marketCap":329004606},{"date":"2021-05-28","current":-4.132171,"twenty":-26.867894,"median":-5.599804,"eighty":-4.337556,"marketCap":338338070},{"date":"2021-06-04","current":-4.02958,"twenty":-26.713113,"median":-5.590157,"eighty":-4.329219,"marketCap":329937952},{"date":"2021-06-11","current":-4.172068,"twenty":-26.335652,"median":-5.580947,"eighty":-4.319219,"marketCap":341604782},{"date":"2021-06-18","current":-3.972584,"twenty":-26.202446,"median":-5.571738,"eighty":-4.312665,"marketCap":325271220},{"date":"2021-06-25","current":-3.972584,"twenty":-25.990306,"median":-5.562528,"eighty":-4.289394,"marketCap":325271220},{"date":"2021-07-02","current":-3.978284,"twenty":-25.700743,"median":-5.544109,"eighty":-4.261723,"marketCap":325737893},{"date":"2021-07-09","current":-3.716105,"twenty":-25.437827,"median":-5.535284,"eighty":-4.243165,"marketCap":304270926},{"date":"2021-07-16","current":-3.402629,"twenty":-25.231092,"median":-5.519914,"eighty":-4.198103,"marketCap":278603900},{"date":"2021-07-23","current":-3.949786,"twenty":-25.078259,"median":-5.495427,"eighty":-4.164896,"marketCap":323404527},{"date":"2021-07-30","current":-3.670508,"twenty":-24.906428,"median":-5.480811,"eighty":-4.145724,"marketCap":300537540},{"date":"2021-08-06","current":-4.063777,"twenty":-24.871308,"median":-5.470433,"eighty":-4.130123,"marketCap":332737991},{"date":"2021-08-13","current":-4.046678,"twenty":-24.778006,"median":-5.452509,"eighty":-4.110274,"marketCap":331337972},{"date":"2021-08-20","current":-3.921288,"twenty":-24.743548,"median":-5.438956,"eighty":-4.084345,"marketCap":321071161},{"date":"2021-08-27","current":-4.422848,"twenty":-24.625161,"median":-5.416804,"eighty":-4.08095,"marketCap":362138403},{"date":"2021-09-03","current":-5.40887,"twenty":-24.551776,"median":-5.416804,"eighty":-4.08095,"marketCap":442872866},{"date":"2021-09-10","current":-4.605234,"twenty":-24.401696,"median":-5.413144,"eighty":-4.08095,"marketCap":377071945},{"date":"2021-09-17","current":-2.787078,"twenty":-24.086818,"median":-5.393865,"eighty":-4.064316,"marketCap":228203194},{"date":"2021-09-24","current":-2.844074,"twenty":-23.824508,"median":-5.365564,"eighty":-4.051837,"marketCap":232869926},{"date":"2021-10-01","current":-2.490702,"twenty":-23.732831,"median":-5.343277,"eighty":-4.045595,"marketCap":203936188},{"date":"2021-10-08","current":-2.792778,"twenty":-23.68117,"median":-5.325657,"eighty":-4.018444,"marketCap":228669868},{"date":"2021-10-15","current":-2.787078,"twenty":-23.430641,"median":-5.30514,"eighty":-4.004501,"marketCap":228203194},{"date":"2021-10-22","current":-3.317136,"twenty":-22.977542,"median":-5.299252,"eighty":-3.983334,"marketCap":271603802},{"date":"2021-10-29","current":-3.100553,"twenty":-22.87288,"median":-5.281588,"eighty":-3.972584,"marketCap":253870220},{"date":"2021-11-05","current":-2.88967,"twenty":-21.845723,"median":-5.270404,"eighty":-3.959051,"marketCap":236603312},{"date":"2021-11-12","current":-2.792778,"twenty":-14.394332,"median":-5.255764,"eighty":-3.943844,"marketCap":228669868},{"date":"2021-11-19","current":-1.612972,"twenty":-13.843611,"median":-5.21682,"eighty":-3.924599,"marketCap":132068515},{"date":"2021-11-26","current":-1.919965,"twenty":-13.675464,"median":-5.205043,"eighty":-3.909868,"marketCap":157204800},{"date":"2021-12-03","current":-1.36767,"twenty":-13.606045,"median":-5.187648,"eighty":-3.890461,"marketCap":133624080},{"date":"2021-12-10","current":-1.507119,"twenty":-13.336084,"median":-5.16652,"eighty":-3.82533,"marketCap":147248496},{"date":"2021-12-17","current":-1.421304,"twenty":-13.01213,"median":-5.139877,"eighty":-3.777975,"marketCap":138864240},{"date":"2021-12-23","current":-1.415941,"twenty":-12.831642,"median":-5.122481,"eighty":-3.761701,"marketCap":138340224},{"date":"2021-12-31","current":-1.38376,"twenty":-7.258026,"median":-5.10648,"eighty":-3.729334,"marketCap":135196128},{"date":"2022-01-07","current":-1.36767,"twenty":-7.101687,"median":-5.098243,"eighty":-3.713451,"marketCap":133624080},{"date":"2022-01-14","current":-1.324763,"twenty":-6.986857,"median":-5.085106,"eighty":-3.691302,"marketCap":129431952},{"date":"2022-01-21","current":-1.39985,"twenty":-6.949072,"median":-5.0789,"eighty":-3.66285,"marketCap":136768176},{"date":"2022-01-28","current":-1.292582,"twenty":-6.851522,"median":-5.063807,"eighty":-3.635351,"marketCap":126287856},{"date":"2022-02-04","current":-1.356943,"twenty":-6.80564,"median":-5.053021,"eighty":-3.596548,"marketCap":132576048},{"date":"2022-02-11","current":-1.292582,"twenty":-6.714753,"median":-5.040178,"eighty":-3.56823,"marketCap":126287856},{"date":"2022-02-18","current":-1.255038,"twenty":-6.620495,"median":-5.031363,"eighty":-3.544478,"marketCap":122619744},{"date":"2022-02-25","current":-1.16386,"twenty":-6.553829,"median":-5.017588,"eighty":-3.533083,"marketCap":113711472},{"date":"2022-03-04","current":-0.92787,"twenty":-6.512358,"median":-5.002826,"eighty":-3.482971,"marketCap":90654768},{"date":"2022-03-11","current":-0.92787,"twenty":-6.43228,"median":-4.988563,"eighty":-3.371615,"marketCap":90654768},{"date":"2022-03-18","current":-1.385235,"twenty":-6.408386,"median":-4.972813,"eighty":-3.325791,"marketCap":135398394},{"date":"2022-03-25","current":-1.509205,"twenty":-6.39428,"median":-4.951548,"eighty":-3.30063,"marketCap":147515760},{"date":"2022-04-01","current":-1.347505,"twenty":-6.379568,"median":-4.929901,"eighty":-3.283177,"marketCap":131710500},{"date":"2022-04-08","current":-1.262866,"twenty":-6.337916,"median":-4.922876,"eighty":-3.262255,"marketCap":123437620},{"date":"2022-04-14","current":-1.090167,"twenty":-6.301122,"median":-4.913177,"eighty":-3.236893,"marketCap":106557262},{"date":"2022-04-22","current":-1.095564,"twenty":-6.241991,"median":-4.902086,"eighty":-3.220358,"marketCap":107084773},{"date":"2022-04-29","current":-0.91207,"twenty":-6.185644,"median":-4.881117,"eighty":-3.175889,"marketCap":89149392},{"date":"2022-05-06","current":-0.798736,"twenty":-6.135197,"median":-4.873684,"eighty":-3.138797,"marketCap":78071657},{"date":"2022-05-13","current":-0.608591,"twenty":-6.121567,"median":-4.86282,"eighty":-3.059997,"marketCap":59486155},{"date":"2022-05-20","current":-0.614558,"twenty":-6.070959,"median":-4.852611,"eighty":-3.029774,"marketCap":60069352},{"date":"2022-05-27","current":-0.638424,"twenty":-6.047024,"median":-4.844588,"eighty":-2.989919,"marketCap":62402143},{"date":"2022-06-03","current":-0.638424,"twenty":-6.036718,"median":-4.833091,"eighty":-2.937031,"marketCap":62402143},{"date":"2022-06-10","current":-0.541109,"twenty":-6.009602,"median":-4.823101,"eighty":-2.913676,"marketCap":52890190},{"date":"2022-06-17","current":-0.379475,"twenty":-5.983448,"median":-4.815003,"eighty":-2.889047,"marketCap":37091367},{"date":"2022-06-24","current":-0.501234,"twenty":-5.967221,"median":-4.80066,"eighty":-2.858016,"marketCap":47822203},{"date":"2022-07-01","current":-0.514437,"twenty":-5.949849,"median":-4.793548,"eighty":-2.843453,"marketCap":49081910},{"date":"2022-07-08","current":-0.599035,"twenty":-5.927041,"median":-4.769327,"eighty":-2.814086,"marketCap":57153364},{"date":"2022-07-15","current":-0.580698,"twenty":-5.895383,"median":-4.758003,"eighty":-2.791148,"marketCap":55403772},{"date":"2022-07-22","current":-0.531124,"twenty":-5.881425,"median":-4.745297,"eighty":-2.780395,"marketCap":50674039},{"date":"2022-07-29","current":-0.531797,"twenty":-5.856593,"median":-4.728723,"eighty":-2.75705,"marketCap":50738191},{"date":"2022-08-05","current":-0.58681,"twenty":-5.834982,"median":-4.705145,"eighty":-2.744997,"marketCap":55986969},{"date":"2022-08-12","current":-0.647936,"twenty":-5.812912,"median":-4.677019,"eighty":-2.72419,"marketCap":61818945},{"date":"2022-08-19","current":-0.600502,"twenty":-5.786106,"median":-4.668815,"eighty":-2.698683,"marketCap":57293332},{"date":"2022-08-26","current":-0.623486,"twenty":-5.773203,"median":-4.64288,"eighty":-2.673473,"marketCap":59486155},{"date":"2022-09-02","current":-0.529718,"twenty":-5.762448,"median":-4.623332,"eighty":-2.631847,"marketCap":50539904},{"date":"2022-09-09","current":-0.543166,"twenty":-5.750446,"median":-4.607121,"eighty":-2.604999,"marketCap":51822938},{"date":"2022-09-16","current":-0.44622,"twenty":-5.7379,"median":-4.598573,"eighty":-2.591014,"marketCap":42573424},{"date":"2022-09-23","current":-0.303491,"twenty":-5.720754,"median":-4.570362,"eighty":-2.551909,"marketCap":28955760},{"date":"2022-09-30","current":-0.307158,"twenty":-5.717846,"median":-4.552593,"eighty":-2.521576,"marketCap":29305679},{"date":"2022-10-07","current":-0.33436,"twenty":-5.703673,"median":-4.54804,"eighty":-2.437886,"marketCap":31900908},{"date":"2022-10-14","current":-0.317122,"twenty":-5.694482,"median":-4.531066,"eighty":-2.395708,"marketCap":30256291},{"date":"2022-10-21","current":-0.341695,"twenty":-5.674113,"median":-4.509064,"eighty":-2.357279,"marketCap":32600745},{"date":"2022-10-28","current":-0.415657,"twenty":-5.658093,"median":-4.48231,"eighty":-2.333847,"marketCap":39657436},{"date":"2022-11-04","current":-0.390779,"twenty":-5.642962,"median":-4.4583,"eighty":-2.324474,"marketCap":37283822},{"date":"2022-11-11","current":-0.400692,"twenty":-5.62856,"median":-4.422848,"eighty":-2.286233,"marketCap":31253559},{"date":"2022-11-18","current":-0.3574,"twenty":-5.613691,"median":-4.403997,"eighty":-2.09484,"marketCap":27876845},{"date":"2022-11-25","current":-0.288462,"twenty":-5.606456,"median":-4.380441,"eighty":-1.744608,"marketCap":22499763},{"date":"2022-12-02","current":-0.185443,"twenty":-5.595202,"median":-4.349694,"eighty":-1.602811,"marketCap":17118785},{"date":"2022-12-09","current":-0.202173,"twenty":-5.583938,"median":-4.337556,"eighty":-1.5262,"marketCap":18663166},{"date":"2022-12-16","current":-0.15875,"twenty":-5.573869,"median":-4.328774,"eighty":-1.488883,"marketCap":14654680},{"date":"2022-12-23","current":-0.156596,"twenty":-5.564548,"median":-4.319248,"eighty":-1.447052,"marketCap":14455840},{"date":"2022-12-30","current":-0.138615,"twenty":-5.553319,"median":-4.318654,"eighty":-1.424522,"marketCap":12795926},{"date":"2023-01-06","current":-0.161931,"twenty":-5.553319,"median":-4.318654,"eighty":-1.415941,"marketCap":14948342},{"date":"2023-01-13","current":-0.195127,"twenty":-5.553319,"median":-4.318654,"eighty":-1.39616,"marketCap":18012797},{"date":"2023-01-20","current":-0.170428,"twenty":-5.553319,"median":-4.318654,"eighty":-1.38376,"marketCap":15732696},{"date":"2023-01-27","current":-0.207576,"twenty":-5.553319,"median":-4.318654,"eighty":-1.364606,"marketCap":19161968},{"date":"2023-02-03","current":-0.226644,"twenty":-5.553319,"median":-4.318654,"eighty":-1.35158,"marketCap":20922206},{"date":"2023-02-10","current":-0.207477,"twenty":-5.553319,"median":-4.318654,"eighty":-1.340853,"marketCap":19152848},{"date":"2023-02-17","current":-0.22615,"twenty":-5.553319,"median":-4.318654,"eighty":-1.314036,"marketCap":20876604},{"date":"2023-02-24","current":-0.217555,"twenty":-5.553319,"median":-4.318654,"eighty":-1.292582,"marketCap":20083129},{"date":"2023-03-03","current":-0.22615,"twenty":-5.553319,"median":-4.318654,"eighty":-1.27971,"marketCap":20876604},{"date":"2023-03-10","current":-0.195523,"twenty":-5.553319,"median":-4.318654,"eighty":-1.242166,"marketCap":18049279},{"date":"2023-03-17","current":-0.134663,"twenty":-5.553319,"median":-4.318654,"eighty":-1.208913,"marketCap":12431110},{"date":"2023-03-24","current":-0.120287,"twenty":-5.553319,"median":-4.318654,"eighty":-1.145625,"marketCap":11104091},{"date":"2023-03-31","current":-0.101022,"twenty":-5.553319,"median":-4.317573,"eighty":-1.104198,"marketCap":9325613},{"date":"2023-04-06","current":-0.080274,"twenty":-5.553319,"median":-4.317573,"eighty":-1.079108,"marketCap":7410328},{"date":"2023-04-14","current":-0.083238,"twenty":-5.553319,"median":-4.318654,"eighty":-0.995449,"marketCap":7683940},{"date":"2023-04-21","current":-0.128,"twenty":-5.553319,"median":-4.318654,"eighty":-0.931343,"marketCap":11816103},{"date":"2023-04-28","current":-0.097185,"twenty":-5.553319,"median":-4.318654,"eighty":-0.895804,"marketCap":8971449},{"date":"2023-05-05","current":-0.125184,"twenty":-5.553319,"median":-4.318654,"eighty":-0.868895,"marketCap":8971843},{"date":"2023-05-12","current":-0.126832,"twenty":-5.553319,"median":-4.318654,"eighty":-0.652572,"marketCap":9089893},{"date":"2023-05-19","current":-0.117498,"twenty":-5.553319,"median":-4.318654,"eighty":-0.638424,"marketCap":8420940},{"date":"2023-05-26","current":-0.119145,"twenty":-5.553319,"median":-4.318654,"eighty":-0.629598,"marketCap":8538991},{"date":"2023-06-02","current":-0.090533,"twenty":-5.553319,"median":-4.318654,"eighty":-0.623486,"marketCap":6488398},{"date":"2023-06-09","current":-0.079422,"twenty":-5.553319,"median":-4.318654,"eighty":-0.614558,"marketCap":5692094},{"date":"2023-06-16","current":-6.390089,"twenty":-5.566178,"median":-4.322542,"eighty":-0.614558,"marketCap":5751080},{"date":"2023-06-23","current":-5.603617,"twenty":-5.574934,"median":-4.329145,"eighty":-0.614558,"marketCap":5043255},{"date":"2023-06-30","current":-3.899592,"twenty":-5.576,"median":-4.334068,"eighty":-0.614558,"marketCap":3509633},{"date":"2023-07-07","current":-4.106041,"twenty":-5.576,"median":-4.333403,"eighty":-0.614558,"marketCap":3695437},{"date":"2023-07-14","current":-4.784374,"twenty":-5.576,"median":-4.328457,"eighty":-0.614558,"marketCap":4305937},{"date":"2023-07-21","current":-6.062392,"twenty":-5.584755,"median":-4.328457,"eighty":-0.614558,"marketCap":5456153},{"date":"2023-07-28","current":-7.041227,"twenty":-5.592019,"median":-4.328774,"eighty":-0.614558,"marketCap":6337104},{"date":"2023-08-04","current":-6.175502,"twenty":-5.603409,"median":-4.344263,"eighty":-0.614558,"marketCap":5557952},{"date":"2023-08-11","current":-5.021202,"twenty":-5.604561,"median":-4.355935,"eighty":-0.614558,"marketCap":4519082},{"date":"2023-08-18","current":0.470508,"twenty":-5.604561,"median":-4.380441,"eighty":-0.608591,"marketCap":5444713},{"date":"2023-08-25","current":0.486292,"twenty":-5.604561,"median":-4.380441,"eighty":-0.599427,"marketCap":5627375},{"date":"2023-09-01","current":0.4442,"twenty":-5.604561,"median":-4.380441,"eighty":-0.593057,"marketCap":5140278},{"date":"2023-09-08","current":0.435093,"twenty":-5.604561,"median":-4.380441,"eighty":-0.581131,"marketCap":5034896},{"date":"2023-09-15","current":0.423907,"twenty":-5.604561,"median":-4.356114,"eighty":-0.573727,"marketCap":4905452},{"date":"2023-09-22","current":0.385007,"twenty":-5.604561,"median":-4.355935,"eighty":-0.567216,"marketCap":4455298},{"date":"2023-09-29","current":0.295964,"twenty":-5.604561,"median":-4.337556,"eighty":-0.560871,"marketCap":3424900},{"date":"2023-10-06","current":0.201155,"twenty":-5.604561,"median":-4.325956,"eighty":-0.551039,"marketCap":2327761},{"date":"2023-10-13","current":0.188203,"twenty":-5.604561,"median":-4.319248,"eighty":-0.535623,"marketCap":2177885},{"date":"2023-10-20","current":0.419794,"twenty":-5.604561,"median":-4.316493,"eighty":-0.531246,"marketCap":4857861},{"date":"2023-10-27","current":0.426778,"twenty":-5.604895,"median":-4.306587,"eighty":-0.527335,"marketCap":4938678},{"date":"2023-11-03","current":0.387363,"twenty":-5.604895,"median":-4.275475,"eighty":-0.511209,"marketCap":4482561},{"date":"2023-11-10","current":0.302313,"twenty":-5.604895,"median":-4.237094,"eighty":-0.492957,"marketCap":3498368},{"date":"2023-11-17","current":0.321064,"twenty":-5.604089,"median":-4.192907,"eighty":-0.462676,"marketCap":3715356},{"date":"2023-11-24","current":0.301835,"twenty":-5.604089,"median":-4.164528,"eighty":-0.438885,"marketCap":3492833},{"date":"2023-12-01","current":1.913375,"twenty":-5.604089,"median":-4.148452,"eighty":-0.414092,"marketCap":22141574},{"date":"2023-12-08","current":2.176247,"twenty":-5.603853,"median":-4.132171,"eighty":-0.404246,"marketCap":25183530},{"date":"2023-12-15","current":1.93822,"twenty":-5.603853,"median":-4.098622,"eighty":-0.389483,"marketCap":22429081},{"date":"2023-12-22","current":2.176247,"twenty":-5.603853,"median":-4.098622,"eighty":-0.380792,"marketCap":25183530},{"date":"2023-12-29","current":2.499284,"twenty":-5.604089,"median":-4.098622,"eighty":-0.374055,"marketCap":28921710},{"date":"2024-01-05","current":2.431276,"twenty":-5.604325,"median":-4.092275,"eighty":-0.359464,"marketCap":28134725},{"date":"2024-01-12","current":1.972224,"twenty":-5.604325,"median":-4.063777,"eighty":-0.335093,"marketCap":22822574},{"date":"2024-01-19","current":1.682171,"twenty":-5.604561,"median":-4.049528,"eighty":-0.329518,"marketCap":19466081},{"date":"2024-01-26","current":1.104445,"twenty":-5.604325,"median":-4.031231,"eighty":-0.317412,"marketCap":12780641},{"date":"2024-02-02","current":1.537001,"twenty":-5.593101,"median":-3.989683,"eighty":-0.3003,"marketCap":17786172},{"date":"2024-02-09","current":1.365795,"twenty":-5.582528,"median":-3.972584,"eighty":-0.281682,"marketCap":15804980},{"date":"2024-02-16","current":1.39557,"twenty":-5.571738,"median":-3.965132,"eighty":-0.228698,"marketCap":16149535},{"date":"2024-02-23","current":1.386073,"twenty":-5.571738,"median":-3.950869,"eighty":-0.225617,"marketCap":16039634},{"date":"2024-03-01","current":1.58115,"twenty":-5.569441,"median":-3.935537,"eighty":-0.222923,"marketCap":18297064},{"date":"2024-03-08","current":1.368105,"twenty":-5.56372,"median":-3.915589,"eighty":-0.221506,"marketCap":15831713},{"date":"2024-03-15","current":1.357838,"twenty":-5.548656,"median":-3.894957,"eighty":-0.213934,"marketCap":15712901},{"date":"2024-03-22","current":1.303678,"twenty":-5.538026,"median":-3.822888,"eighty":-0.210528,"marketCap":15086167},{"date":"2024-03-28","current":1.314459,"twenty":-5.528344,"median":-3.777769,"eighty":-0.207477,"marketCap":15210920},{"date":"2024-04-05","current":1.492285,"twenty":-5.494378,"median":-3.755539,"eighty":-0.195285,"marketCap":17268724},{"date":"2024-04-12","current":0.605068,"twenty":-5.475007,"median":-3.716105,"eighty":-0.185834,"marketCap":14470801},{"date":"2024-04-19","current":0.560697,"twenty":-5.462246,"median":-3.670508,"eighty":-0.177877,"marketCap":13409631},{"date":"2024-04-26","current":0.554625,"twenty":-5.452212,"median":-3.626669,"eighty":-0.176652,"marketCap":13264413},{"date":"2024-05-03","current":0.600271,"twenty":-5.439673,"median":-3.563943,"eighty":-0.169302,"marketCap":14356080},{"date":"2024-05-10","current":0.610264,"twenty":-5.416804,"median":-3.501611,"eighty":-0.165725,"marketCap":14595083},{"date":"2024-05-17","current":0.643176,"twenty":-5.41321,"median":-3.330382,"eighty":-0.158671,"marketCap":15382198},{"date":"2024-05-24","current":0.606267,"twenty":-5.39599,"median":-3.265474,"eighty":-0.143179,"marketCap":14499482},{"date":"2024-05-31","current":0.610664,"twenty":-5.370863,"median":-3.151849,"eighty":-0.138219,"marketCap":14604643},{"date":"2024-06-07","current":0.615061,"twenty":-5.36699,"median":-3.035009,"eighty":-0.135312,"marketCap":14709804},{"date":"2024-06-14","current":0.532982,"twenty":-5.362512,"median":-2.906769,"eighty":-0.130565,"marketCap":12746797},{"date":"2024-06-21","current":0.493008,"twenty":-5.363325,"median":-2.838375,"eighty":-0.125843,"marketCap":11790787},{"date":"2024-06-28","current":0.502602,"twenty":-5.366866,"median":-2.809877,"eighty":-0.125234,"marketCap":12020230},{"date":"2024-07-05","current":0.483148,"twenty":-5.366866,"median":-2.787078,"eighty":-0.119991,"marketCap":11554972},{"date":"2024-07-12","current":0.512862,"twenty":-5.366866,"median":-2.747182,"eighty":-0.118047,"marketCap":12265605},{"date":"2024-07-15","current":0.518325,"twenty":-5.359262,"median":-2.747182,"eighty":-0.117827,"marketCap":12396260},{"date":"2024-08-02","current":1.012666,"twenty":-5.335917,"median":-2.641739,"eighty":-0.1164,"marketCap":24218915},{"date":"2024-08-09","current":0.604935,"twenty":-5.335917,"median":-2.467904,"eighty":-0.109667,"marketCap":14467615},{"date":"2024-08-16","current":0.501967,"twenty":-5.335917,"median":-1.807967,"eighty":-0.098799,"marketCap":12005053},{"date":"2024-08-23","current":0.510267,"twenty":-5.328557,"median":-1.693626,"eighty":-0.090533,"marketCap":12203536},{"date":"2024-08-30","current":-0.36582,"twenty":-5.311028,"median":-1.560752,"eighty":-0.08436,"marketCap":11038246},{"date":"2024-09-06","current":-0.379824,"twenty":-5.299252,"median":-1.508162,"eighty":-0.08436,"marketCap":11460824},{"date":"2024-09-13","current":-0.455789,"twenty":-5.270058,"median":-1.47322,"eighty":-0.08436,"marketCap":13752988},{"date":"2024-09-20","current":-0.410805,"twenty":-5.234497,"median":-1.432031,"eighty":-0.08436,"marketCap":12395617},{"date":"2024-09-27","current":-0.395527,"twenty":-5.203358,"median":-1.418622,"eighty":-0.08436,"marketCap":11934623},{"date":"2024-10-04","current":-0.345661,"twenty":-5.193267,"median":-1.403323,"eighty":-0.08436,"marketCap":10429990},{"date":"2024-10-11","current":-0.343752,"twenty":-5.193267,"median":-1.38376,"eighty":-0.08436,"marketCap":10372365},{"date":"2024-10-18","current":-0.348208,"twenty":-5.193267,"median":-1.36384,"eighty":-0.08436,"marketCap":10506822},{"date":"2024-10-25","current":-0.339084,"twenty":-5.17761,"median":-1.35158,"eighty":-0.08436,"marketCap":10231506},{"date":"2024-10-31","current":-0.353937,"twenty":-5.135696,"median":-1.342336,"eighty":-0.08436,"marketCap":10679695},{"date":"2024-11-08","current":-0.346298,"twenty":-5.10423,"median":-1.314036,"eighty":-0.084278,"marketCap":10449198},{"date":"2024-11-15","current":-0.296645,"twenty":-5.084766,"median":-1.292582,"eighty":-0.084278,"marketCap":8950967},{"date":"2024-11-22","current":-0.286035,"twenty":-5.078031,"median":-1.276492,"eighty":-0.084278,"marketCap":8630832},{"date":"2024-11-29","current":-0.360727,"twenty":-5.059035,"median":-1.244311,"eighty":-0.084278,"marketCap":10884581},{"date":"2024-12-06","current":-0.305982,"twenty":-5.042774,"median":-1.217494,"eighty":-0.084278,"marketCap":9232686},{"date":"2024-12-13","current":-0.303011,"twenty":-5.022362,"median":-1.14777,"eighty":-0.084278,"marketCap":9143048},{"date":"2024-12-20","current":-0.274577,"twenty":-5.000024,"median":-1.106357,"eighty":-0.084278,"marketCap":8285087},{"date":"2024-12-27","current":-0.277972,"twenty":-4.986767,"median":-1.079373,"eighty":-0.084278,"marketCap":8387530},{"date":"2025-01-03","current":-0.271606,"twenty":-4.957126,"median":-1.036198,"eighty":-0.084278,"marketCap":8195449},{"date":"2025-01-10","current":-0.265665,"twenty":-4.931523,"median":-0.966039,"eighty":-0.084196,"marketCap":8016174},{"date":"2025-01-17","current":-0.241607,"twenty":-4.918819,"median":-0.917288,"eighty":-0.084196,"marketCap":7290236},{"date":"2025-01-24","current":-0.277336,"twenty":-4.88698,"median":-0.890327,"eighty":-0.084196,"marketCap":8368322},{"date":"2025-01-31","current":-0.25166,"twenty":-4.859922,"median":-0.742447,"eighty":-0.084196,"marketCap":7593596},{"date":"2025-02-07","current":-0.248265,"twenty":-4.846178,"median":-0.647936,"eighty":-0.084196,"marketCap":7491153},{"date":"2025-02-14","current":-0.22747,"twenty":-4.846178,"median":-0.634084,"eighty":-0.084196,"marketCap":6863689},{"date":"2025-02-21","current":-0.207949,"twenty":-4.846178,"median":-0.628045,"eighty":-0.084196,"marketCap":6274641},{"date":"2025-02-28","current":-0.152779,"twenty":-4.846178,"median":-0.623486,"eighty":-0.084196,"marketCap":4609940},{"date":"2025-03-07","current":-0.133257,"twenty":-4.8476,"median":-0.608591,"eighty":-0.084113,"marketCap":4020892},{"date":"2025-03-14","current":-0.11034,"twenty":-4.8476,"median":-0.599158,"eighty":-0.084113,"marketCap":3329401},{"date":"2025-03-21","current":-0.118828,"twenty":-4.8476,"median":-0.592189,"eighty":-0.084113,"marketCap":3585509},{"date":"2025-03-28","current":-0.116706,"twenty":-4.8476,"median":-0.580575,"eighty":-0.084113,"marketCap":3521482},{"date":"2025-04-04","current":-0.095911,"twenty":-4.8476,"median":-0.571658,"eighty":-0.084113,"marketCap":2894018},{"date":"2025-04-11","current":-0.430563,"twenty":-4.827704,"median":-0.566701,"eighty":-0.083784,"marketCap":3559898},{"date":"2025-04-17","current":-0.438637,"twenty":-4.818658,"median":-0.560889,"eighty":-0.083784,"marketCap":3626654},{"date":"2025-04-25","current":-0.491613,"twenty":-4.794147,"median":-0.549707,"eighty":-0.083702,"marketCap":4064656},{"date":"2025-05-02","current":-0.45559,"twenty":-4.7651,"median":-0.534731,"eighty":-0.083702,"marketCap":3766815},{"date":"2025-05-05","current":-0.438637,"twenty":-4.76208,"median":-0.534303,"eighty":-0.083702,"marketCap":3626654}],"updateTime":1746588539328}}}